Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection

Hye Won Lee; Seung Up Kim; Oidov Baatarkhuu; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang Hyub Han; Beom Kyung Kim

doi:10.1016/j.cgh.2019.01.002

Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection

Hye Won Lee, Seung Up Kim, Oidov Baatarkhuu, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang Hyub Han, Beom Kyung Kim

Department of Internal Medicine

Research output: Contribution to journal › Short survey › peer-review

13 Citations (Scopus)

Abstract

Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellular carcinoma (HCC) or cirrhosis; (1) elevated serum hepatitis B virus (HBV)-DNA (≥20,000 IU/mL for hepatitis B e antigen–positive chronic hepatitis B [CHB] or ≥2000 IU/mL for hepatitis B e antigen–negative CHB) and (2) serum alanine aminotransferase ≥2× upper limit of normal.¹ Therefore, many patients still remain untreated. Such untreated patients have so called “minimally active CHB,” where serum HBV-DNA is persistently >2000 IU/mL and other parameters for NUCs are below the criteria.² There have been little data concerning their prognosis.

Original language	English
Pages (from-to)	2808-2810.e2
Journal	Clinical Gastroenterology and Hepatology
Volume	17
Issue number	13
DOIs	https://doi.org/10.1016/j.cgh.2019.01.002
Publication status	Published - 2019 Dec

Bibliographical note

Publisher Copyright:
© 2019 AGA Institute

All Science Journal Classification (ASJC) codes

Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cgh.2019.01.002

Cite this

@article{940eb265beaf4a1c88f12b603c7881c0,

title = "Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection",

abstract = "Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellular carcinoma (HCC) or cirrhosis; (1) elevated serum hepatitis B virus (HBV)-DNA (≥20,000 IU/mL for hepatitis B e antigen–positive chronic hepatitis B [CHB] or ≥2000 IU/mL for hepatitis B e antigen–negative CHB) and (2) serum alanine aminotransferase ≥2× upper limit of normal.1 Therefore, many patients still remain untreated. Such untreated patients have so called “minimally active CHB,” where serum HBV-DNA is persistently >2000 IU/mL and other parameters for NUCs are below the criteria.2 There have been little data concerning their prognosis.",

author = "Lee, {Hye Won} and Kim, {Seung Up} and Oidov Baatarkhuu and Park, {Jun Yong} and Kim, {Do Young} and Ahn, {Sang Hoon} and Han, {Kwang Hyub} and Kim, {Beom Kyung}",

note = "Publisher Copyright: {\textcopyright} 2019 AGA Institute",

year = "2019",

month = dec,

doi = "10.1016/j.cgh.2019.01.002",

language = "English",

volume = "17",

pages = "2808--2810.e2",

journal = "Clinical Gastroenterology and Hepatology",

issn = "1542-3565",

publisher = "W.B. Saunders Ltd",

number = "13",

}

TY - JOUR

T1 - Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection

AU - Lee, Hye Won

AU - Kim, Seung Up

AU - Baatarkhuu, Oidov

AU - Park, Jun Yong

AU - Kim, Do Young

AU - Ahn, Sang Hoon

AU - Han, Kwang Hyub

AU - Kim, Beom Kyung

PY - 2019/12

Y1 - 2019/12

N2 - Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellular carcinoma (HCC) or cirrhosis; (1) elevated serum hepatitis B virus (HBV)-DNA (≥20,000 IU/mL for hepatitis B e antigen–positive chronic hepatitis B [CHB] or ≥2000 IU/mL for hepatitis B e antigen–negative CHB) and (2) serum alanine aminotransferase ≥2× upper limit of normal.1 Therefore, many patients still remain untreated. Such untreated patients have so called “minimally active CHB,” where serum HBV-DNA is persistently >2000 IU/mL and other parameters for NUCs are below the criteria.2 There have been little data concerning their prognosis.

AB - Nucleos(t)ide analogs (NUCs) are recommended when both are fulfilled in the absence of hepatocellular carcinoma (HCC) or cirrhosis; (1) elevated serum hepatitis B virus (HBV)-DNA (≥20,000 IU/mL for hepatitis B e antigen–positive chronic hepatitis B [CHB] or ≥2000 IU/mL for hepatitis B e antigen–negative CHB) and (2) serum alanine aminotransferase ≥2× upper limit of normal.1 Therefore, many patients still remain untreated. Such untreated patients have so called “minimally active CHB,” where serum HBV-DNA is persistently >2000 IU/mL and other parameters for NUCs are below the criteria.2 There have been little data concerning their prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85069514951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069514951&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2019.01.002

DO - 10.1016/j.cgh.2019.01.002

M3 - Short survey

C2 - 30639778

AN - SCOPUS:85069514951

SN - 1542-3565

VL - 17

SP - 2808-2810.e2

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

IS - 13

ER -

Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this